Lund, Sweden, September 12, 2012 – SARomics Biostructures AB, the leading
Scandinavian structural biology service provider, is pleased to announce that
Innovationsbron AB and Lund University Innovation System AB (LUIS AB) are investing
in and becoming new co-owners of the company alongside the founders.
The new investment will allow the company to expand its primary business of generating
3D structural information of proteins and protein-ligand complexes. SARomics
Biostructures is a major user of MAX-lab, the Swedish national synchrotron facility in
Lund, and aims to position itself as a leading European structural biology service provider
when the new world-class MAX IV synchrotron opens in 2015.
Linus Wiebe, CEO of LUIS said “SARomics Biostructures has shown the commercial
potential of MAX-lab and we believe that our strategic investment will leverage the
company to take full advantage of MAX IV in the future”
SARomics Biostructures gene-to-structure platform has successfully been applied to
determine structures of many important drug targets, biopharmaceuticals, and industrial
enzymes for partners from both the life science industry and academia worldwide. The
company is currently expanding its off-the-shelf portfolio of “ready made” crystal
structures of important drug targets and will also engage in internal lead discovery
About SARomics Biostructures
SARomics Biostructures is the leading Scandinavian provider of structural biology and in
silico drug discovery services. The company accelerates its customers’ drug discovery
processes by providing structure-based drug design support including protein
crystallization, X-ray protein structure determination, computational chemistry, protein
modeling and NMR spectroscopy analyses. The company is equipped with state-of-the-art
robotics for low volume high-throughput crystallization and X-ray diffraction experiments.
Its strategic location close to the MAX-lab synchrotron radiation facility provides the
company with instant access to beamlines and eliminates the need for crystal
transportation to remote synchrotrons. For further general information please visit
www.saromics.com or contact Dr. Björn Walse, CEO at email@example.com.
Founded in 1994, Innovationsbron develops and invests in companies with an
international growth potential. The investment in SARomics Biostructures AB is part of a
co-investment project with European Regional Development Fund (ERDF).
Innovationsbron will be represented in the board by Investment Manager Per Antonsson.
For more information please visit www.innovationsbron.se or contact Information
Manager Maria Kessling (+46 768 808810) or Per Antonsson (+46 708 728717).
Lund University Innovation System AB (LUIS AB) supports and finances the
commercialisation process for new unique ideas emanating from research results at Lund
University. Through LUIS AB, the University can form new research-based companies
and assist inventors in creating licensing deals. Any profit made when selling the shares
or receiving revenue from licensing deals is used to support new commercialisation
projects. LUIS AB currently holds equity in 38 spin-out companies. Read more about
LUIS at luis.lu.se